Cargando…
Dexamethasone/tocilizumab: Worsening of hepatitis E virus infection following off label use: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853891/ http://dx.doi.org/10.1007/s40278-022-10247-5 |
Ejemplares similares
-
Dexamethasone/prednisone/tocilizumab: Worsening of Strongyloides infection: case report
Publicado: (2020) -
Dexamethasone/tocilizumab: Lack of efficacy following off-label therapy: case report
Publicado: (2022) -
Tocilizumab: Infection and worsening of pre-existing COVID-19 symptoms following off-label treatment: case report
Publicado: (2021) -
Dexamethasone/remdesivir/tocilizumab: Methaemoglobinaemia and off-label use: case report
Publicado: (2021) -
Dexamethasone/tocilizumab: Off-label-use and lack of efficacy: case report
Publicado: (2021)